Tuesday | Wednesday | Thursday | Friday
TUESDAY, DECEMBER 7, 2021
All times are CENTRAL Time
 
     
7:45 am - 8:00 am CT WELCOME AND OPENING REMARKS - Hall 3  
 

Virginia G. Kaklamani, MD
UT Health San Antonio MD Anderson Cancer Center
San Antonio, TX

Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX

 
8:00 am - 10:45 am CT
GENERAL SESSION 1 - Hall 3
 
8:00 am - 8:15 am CT  GS1-00 Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial
Bianchini G, Wang XQ, Danenberg E, Huang C-S, Egle D, Callari M, Bermejo B, Zamagni C, Thill M, Anton A, Dugo M, Zambelli S, Russo S, Ciruelos EM, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Győrffy B, Biasi O, Valagussa P, Viale G, Gianni L, Ali HR. San Raffael Scientific Institute, Milano, Italy; CRUK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom; National Taiwan University Hospital and Taiwan Breast Cancer Consortium, Taipei, Taiwan; Department of Gynecology, BrustGesundheitZentrum Tirol, Medical University Innsbruck, Innsbruck, Austria; Hospital Clinico Universitario Valencia and GEICAM, Valencia, Spain; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany; Hospital Universitario Miguel Servet and GEICAM, Zaragoza, Spain; Ospedale Santa Maria della Misericordia, Udine, Italy; Hospital Universitario 12 de octubre, Madrid, Spain; IIIrd Medical Department, Paracelsus Medical University Salzburg; Salzburg Cancer Research Institute-CCCIT; Cancer Cluster Salzburg, Salzburg, Austria; NN Petrov Research Inst of Oncology, St. Petersburg, Russian Federation; IRCCS Istituto Europeo di Oncologia, Milano, Italy; Cancer Trials Ireland & Mater Misericordiae University Hospital, Dublin, Ireland; Istituto Nazionale Tumori, Milano, Italy; Università degli Studi di Genova, Ospedale Policlinico San Martino, Genova, Italy; Ospedale San Raffaele, Milano, Italy; Fondazione Michelangelo, Milano, Italy; University of Milan, Istituto Europeo di Oncologia IRCCS, Milano, Italy.
 
8:15 am GS1-01 KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Hee Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier M-A, Im S-A, Ahn J-H, Gion M, Baron-Hay S, Boileau J-F, Zhu Y, Pan W, Tryfonidis K, Karantza V, O’Shaughnessy J. Barts Cancer Institute, Queen Mary University London, London, United Kingdom; International Breast Cancer Center, Quiron Group, Madrid and Barcelona, Spain and Vall d'Hebron Institute of Oncology, Barcelona, Spain; National Cancer Center Singapore, Duke-NUS Medical School, Singapore, Singapore; Yale School of Medicine, Yale Cancer Center, New Haven, CT; Cedars-Sinai Medical Center, Los Angeles, CA; Kliniken Essen-Mitte, Essen, Germany; Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Centre, Cancer theme, Karolinska University Hospital, Solna, Sweden; Institute of Pathology, Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, Germany; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Westmead Breast Cancer Institute, Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Breast Center, Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany; Hokkaido Cancer Center, Sapporo, Japan; Breast Cancer Center, HELIOS Klinikum Berlin-Buch GmbH, Berlin, Germany; University Hospital Erlangen, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal; Compass Oncology, US Oncology, Portland, OR; Texas Oncology, Austin, TX; Virginia Oncology Associates, Norfolk, VA; Instituto Português de Oncologia do Porto Francisco Gentil (IPO-Porto), Porto, Portugal; Centre Jean-Perrin, Clermont-Ferrand, France; Seoul National University, Seoul, Republic of KoreaAsan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of KoreaRamon y Cajal University Hospital, Madrid, Spain; Royal North Shore Hospital, Sydney, NSW, Australia; McGill University, Jewish General Hospital Segal Cancer Centre, Montréal, QC, Canada;; Merck & Co., Inc., Kenilworth, NJ; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX.
 
8:30 am GS1-02 Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MMd, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P. International Breast Cancer Center, Quiron Group, Madrid and Barcelona, Spain and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Seoul National University Hospital, Seoul, Republic of KoreaPantai Hospital, Kuala Lumpur, MalaysiaArturo Lopez Perez Foundation, Santiago, Chile; Republican Clinical Oncology Dispensary, Republic of Bashkortostan, Russian Federation; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; International Breast Cancer Center, Quiron Group, Barcelona, Spain;Aichi Cancer Center Hospital, Nagoya, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Oncomedica S.A., Monteria, ColombiaEge University Medical Faculty, Izmir, Turkey; Peter McCallum Cancer Institute, Melbourne, Australia; Merck & Co., Inc., Kenilworth, NJ; Barts Cancer Institute, Centre for Experimental Cancer Medicine, London, United Kingdom.
 
8:45 am GS1-03 Discussant
Hope S. Rugo, MD
University of California San Francisco
San Francisco, CA
 
9:00 am  GS1-04 TBD  
9:15 am  GS1-05 Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study
Krop I, Juric D, Shimizu T, Tolcher A, Spira A, Mukohara T, Lisberg AE, Kogawa T, Papadopoulos KP, Hamilton E, Damodaran S, Greenberg J, Gu W, Kobayashi F, Guevara F, Jikoh T, Kawasaki Y, Meric-Bernstam F, Bardia A. Dana-Farber Cancer Institute, Boston, MA; Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center Harvard Medical School, Boston, MA; National Cancer Center Hospital, Tokyo, JapanNEXT Oncology, San Antonio, TX; Virginia Cancer Specialists, Fairfax, VA; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; UCLA Jonsson Comprehensive Cancer Center, Santa Monica, CA; Advanced Medical Development Center, Cancer Institute Hospital of JFCR, Tokyo, Japan; START Center for Cancer Care San Antonio, San Antonio, TX; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; Daiichi Sankyo Inc, Basking Ridge, NJ; Daiichi Sankyo Co, Ltd, Tokyo, Japan.
 
9:30 am  GS1-06 A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer
Xu B, Zhang Q, Hu X, Li Q, Sun T, Li W, Ouyang Q, Wang J, Tong Z, Yan M, Li H, Zeng X, Shan C, Wang X, Yan X, Zhang J, Zhang Y, Wang J, Zhang L, Lin Y, Feng J, Chen Q, Huang J, Lu Y, Li H, Wu J, Cheng J, Hao Y, Geng C, Lu M, Li Y, Chen X, Song L, Wu X, Hu C, Wu X, Wang X, Pan Y, Cui Y, Guohua Yu, Sun S. Cancer Hospital Chinese Academy of Medical Sciences, Beijing, ChinaHarbin Medical University Cancer Hospital, Harbin, ChinaFudan University Shanghai Cancer Center, Shanghai, ChinaLiaoning Cancer Hospital & Institute, Liaoning, ChinaThe First Hospital of Jilin University, Jilin, ChinaHunan Cancer Hospital, Changsha, ChinaLinyi Cancer Hospital, Shandong, ChinaTianjin Medical University Cancer Institute & Hospital, Tianjin, ChinaHenan Cancer Hospital, Zhengzhou, ChinaBeijing Cancer Hospital, Beijing, China; Chongqing University Cancer Hospital, Chongqing, ChinaAffiliated Hospital of Jining Medical University, Jining, China; Run Run Shaw Hospital, Affiliated Hospital of Zhejiang University, Hangzhou, China; West China Hospital, Sichuan University, Chengdu, China; The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaJiangsu Cancer Hospital, Nanjing, China; Guangdong Hospital of Traditional Chinese Medicine, Guangzhou, China; The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Guangxi Medical University Cancer Hospital, Guangxi, China; Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China; The First Affiliated Hospital of Hainan Medical University, Haikou, China; Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China; The Peoples Hospital of Guangxi Zhuang Autonomous Region, Nanning, China; The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital, Shijiazhuang, China; Beijing Shijitan Hospital, Capital Medical University, Beijing, China; Fuzhou General Hospital, Fuzhou, China; Shandong Cancer Hospital, Jinan, China; Taizhou EOC Pharma Co., Ltd., Taizhou, China; Anhui Provincial Cancer Hospital, Hefei, China; Hubei Cancer Hospital, Wuhan, China; Zhejiang Cancer Hospital, Hangzhou, China; Anhui Provincial Hospital, Hefei, ChinaZhongshan Hospital, Fudan University, Shanghai, China; Weifang People's Hospital, Weifang, China; Xuzhou Central Hospital, Xuzhou, China.
 
9:45 am  GS1-07 Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial
Gnant M, Dueck AC, Frantal S, Martin M, Burstein H, Greil R, Fox P, Wolff AC, Chan A, Winer E, Singer C, Miller K, Colleoni M, Naughton M, Rubovszky G, Bliss J, Mayer IA, Steger GG, Nowecki Z, Hahn O, Wolmark W, Rugo H, Pfeiler G, Fohler H, Metzger O, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A*, and Mayer EL *shared last authorship. Medical University of Vienna, Vienna, Austria; Alliance Statistics and Data Center, Mayo Clinic, Phoenix, AZ; ABCSG, Vienna, Austria; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Dana-Farber Cancer Institute, Boston, MA; Salzburg Cancer Research Institute– Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR) Paracelsus Medical University, Salzburg, Austria; Central West Cancer Care Centre, Orange Health Service, Orange; NSW, Australia; Johns Hopkins University, Baltimore, MD; Breast Cancer Research Centre -WA, Perth, Australia; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN; IEO, European Institute of Oncology, IRCCS, Milan, Italy; The Ohio State University, Columbus, OH; National Institute of Oncology, Budapest, Hungary; The Institute of Cancer Research, London, United Kingdom; Vanderbilt University, Nashville, TN; The Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; University of Chicago, Chicago, IL; NSABP/NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; BIG, Brussels, Belgium; Pfizer, Cambridge, MA; Pfizer, La Jolla, CA; Mayo Clinic, Rochester, MN; University of Pennsylvania, Philadelphia, PA.
 
10:00 am  GS1-08 CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438)
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey RR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR. Mount Sinai Hospital/Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, CanadaCanadian Cancer Trials Group, Queens University, Kingston, ON, CanadaBritish Columbia Cancer Agency, University of British Columbia, Vancouver, BC, CanadaJuravinski Cancer Center, McMaster University, Hamilton, ON, CanadaApplied Statistician, Toronto, ON, CanadaCHU de Quebec, University Laval, Quebec City, QC, CanadaDana Farber Cancer Center, Harvard University, Boston, MA; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY; Vanderbilt University, Nashville, TN; Mayo Clinic, Rochester, MN; Institute of Cancer Research, London, United KingdomNRG Oncology, University of Pittsburgh, Pittsburgh, PA; IBCSG, Department of Oncology, University of Bern, Berne, SwitzerlandJuravinski Cancer Centre, McMaster University, Hamilton, ON, CanadaCross Cancer Institute, Edmonton, AB, CanadaVanderbilt-Ingram Cancer Center, Nashville, TN; British Columbia Cancer Agency, University of British Columbia, Surrey, BC, Canada; James Cancer Hospital and the Ohio State University Comprehensive Cancer Center, Columbus, OH; Baylor College of Medicine, Houston, TX; CRTCU, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United KingdomPrincess Margaret Cancer Center, University Health Network, Dept of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
 
10:15 am  GS1-09 Inhibition of GPX4 induces preferential death of p53-mutant triple-negative breast cancer cells
Tahaney WM, Qian J, Powell R, Moyer CL, Ma Y, Nguyen N, Hill J, Stephan C, Mazumdar A, Davies PJA, Brown PH. Baylor College of Medicine, Houston, TX; UT MD Anderson Cancer Center, Houston, TX; Texas A&M Institute for Biosciences and Technology, Houston, TX.
 
10:30 am GS1-10 Clinical utility of molecular tumor profiling: Results from the randomized trial SAFIR02-BREAST
André F, Gonçalves A, Filleron T, Dalenc F, Lusque A, Campone M, Sablin M-P, Bonnefoi H, Bieche I, Lacroix L, Tran-Dien A, Jimenez M, Jacquet A, Wang Q, Rouleau E, Gentien D, Soubeyran I, Morel A, Arnedos M, Bachelot T. Gustave Roussy-Department of Medical Oncology, Villejuif, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; Institut de Cancérologie de l’Ouest, ST-HERBLAIN, France; Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; Institut Curie and Paris-Descartes University-Department of Medical Oncology, Paris, France; Gustave Roussy-Department of Medical Biology and Pathology, BMO Unit - AMMICa UMS3655/US23, Villejuif, France; Gustave Roussy Cancer Campus-Inserm UMR981 and Department of Medical Oncology, Villejuif, France; Unicancer, Paris, France; Centre Léon Bérard-Département de Recherche Translationnelle et d’Innovation, Lyon, France; Institut Curie-Genomics Platform, Translational Research Department. PSL University, Paris, France; Institut Bergonié-nité de Pathologie Moléculaire - Département de Biopathologie, Bordeaux, France; ICO- Centre Paul Papin-Department of Innate Immunity and Immunotherapy, Angers, France; Centre Léon Bérard-Department of Medical Oncology, Lyon, France
 
10:00 am - 5:00 pm CT EXHIBITS - Hall 2  
10:45 am - 11:00 am CT BREAK  
11:00 am - 1:00 pm CT COVID - 19 and Cancer - Hall 4A  
 

Sub-Session: Living in the COVID generation – Vaccinations and Patient Perspectives
Moderator: Susan Rafte
Community Advocate Baylor College of Medicine
Houston, MD

TBD
Peter Hotez, MD
Baylor College of Medicine
Houston, TX

Patient Advocates

Abigail Johnston
Sharon Anderson
Isabel Centeno

 
 

Sub-Session: How COVID changed "everything"
Moderator: Melissa L. Bondy, PhD
Stanford Medicine
Stanford, CA 

How COVID changed cancer center operations
Debra Patt, MD, PhD
Texas Oncology
Austin, TX

How COVID changed clinical trials
Ko Un (Clara) Park, MD
The Ohio State University
Columbus, OH

How COVID changed regulatory aspects
Donna Rivera, PharmD
US Food & Drug Administration
Baltimore, MD

 
 

Sub-Session: Impact of COVID across Cancer Continuum
Moderator: Ko Un (Clara) Park, MD
The Ohio State University
Columbus, OH

Challenges in breast cancer supportive care during COVID 19 and beyond
Maryam Lustberg, MD, MPH
Yale University School of Medicine
New Haven, CT

Importance of real world data in fighting a pandemic
Dimpy Shah, MD, PhD
UT Health San Antonio
San Antonio, TX

The impact of the COVID-19 outbreak on breast cancer stage in the Netherlands by screening status
Anouk H. Eijkelboom
Netherlands Comprehensive Cancer Organization
Utrecht, Netherlands

National claims data analysis of breast cancer diagnosis and treatment before versus during the COVID-19 pandemic
Jennifer L. Caswell-Jin, MD
Stanford University
Stanford, CA 

 
11:00 am - 1:00 pm CT WORKSHOPS  
 

Clinical Research: From Study Design to Scientific Presentation Stars at Night Ballroom 1&2
Moderator: Aditya Bardia, MD, MPH
Massachusetts General Hospital
Boston, MA

Selecting rational biomarkers for clinical and translational studies
Justin Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN

How to design an efficient clinical study
Valentina Nekljudova, PhD
German Breast Group
Neu-Isenburg, Germany

How to include patient advocates in clinical research
Patty Spears
University of North Carolina at Chapel Hill
Chapel Hill, NC

How to present clinical research results effectively
George W. Sledge, Jr, MD
Stanford University School of Medicine
Stanford, CA

Basic Workshop: Basic Science for Breast Oncologists - Stars at Night Ballroom 3&4
Moderator: Alana Welm, PhD
University of Utah Huntsman Cancer Institute
Salt Lake City, UT

Genome editing in human organoids as new models for discovery
Jennifer Rosenbluth, MD, PhD
University of California San Francisco
San Francisco, CA

In silico experimentation from your living room: Tools to access and analyze existing datasets
Daniel Stover, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH

Tricking T cells into action: Using patient-derived organoids to identify and expand tumor-specific T cells
Senthil K. Muthuswamy, PhD
Beth Israel Deaconess Medical Center
Boston, MA

Meeting the bar: How to tell when basic science discoveries are ready to translate
Bora Lim, MD
Baylor College of Medicine
Houston, TX

 
1:00 pm - 4:00 pm CT SPECIAL SESSION - Hall 3  
 

Trust in Science and Healthcare
Co-Moderator: Charles M. Perou, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC

Co-Moderator: Maimah Karmo
Tigerlily Foundation
Stone Ridge, VA

Keynote

Lori L. Wilson

Panel 1: Equity in Research and Patient Care
Deborah Stroman, PhD, CLU, UNC and Project Ground Water (Virtual)
Olufunmilayo I. Olopade, MD, FACP, Director, University of Chicago
Daniel Calac, MD, Chief Medical Officer, Indian Health Council, Inc
Maria Elena Martinez, UCSD
George Sledge, Stanford
 Lisa C. Richardson, MD – Director, Division of Cancer Prevention and Control, CDC

Patient Advocates
Darcy Burbage, DNP, RN, AOCN
Newark, DE

Na'Diah Smith,Tigerlily Foundation Breast Cancer ANGEL Advocate

Aliya Whipple, Tigerlilly Foundation Breast Cancer ANGEL Advocate

Keynote #2
Charles M. Perou, PhD

Panel 2: Diversity in Clinical Trials
Erica Stringer-Reasor, MD
UAB Medicine
Birmingham, AL

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA 

Amelie Ramirez
UT Health San Antonio

Melissa Davis, NYU

Sophia George, University of Miami Cancer Center

Lori L. Wilson

Patient Advocates 
Thelma Brown TBCRC patient advocate of color/AA - advocate

Ashley Dedmon, MPH, CHES
Tigerlily Foundation Breast Cancer ANGEL Advocate

Ysabel Duron
The Latino Cancer Institute

 

 
4:00 pm - 5:00 pm CT Susan G. Komen®  Brinker Awards for Scientific Distinction Lectures - Hall 3  
  Brinker Award for Scientific Distinction in Basic Science
Carlos Caldas, MD
University of Cambridge
Cambridge, United Kingdom
 
  Brinker Award for Scientific Distinction in Clinical Research
Judy Garber, MD, MPH
Dana Farber Cancer Institute
Boston, MA
 
     
5:00 pm - 7:00 pm CT

EDUCATIONAL SESSIONS 

Updates on advances in key areas and in technologies available for translational research. Many of these sessions will provide attendees with a better understanding of the background leading up to talks they will hear in the succeeding days, and some of the techniques that will be used. These presentations should also provide researchers with ideas and techniques to be considered for their own studies.

 

Triple Positive Breast Cancer - Stars at Night Ballroom 1&2 
Moderator: Jenny C. Chang, MD, MB BChir
Houston Methodist Hospital
Houston, TX

The ideal partner to HER2 directed therapies
Sara A. Hurvitz, MD
UCLA
Los Angeles, CA

ER/HER2+ cross talk
Charles M. Perou, PhD
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Escalating and de-escalation - titrating the right regimen in early stage HER2 positive
Nadia Harbeck, MD, PhD
University of Munich
Munich, Germany

Artificial Intelligence: Beyond the Soundbites supported by Lobular Breast Cancer Alliance - Stars at Night Ballroom 3&4
Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Everything you always wanted to know about AI but were afraid to ask
Regina Barzilay, PhD
MIT
Cambridge, MA

Artificial intelligence: Guiding the pathologists' eyes
Thomas J. Fuchs
Memorial Sloan Kettering Cancer Center
New York, NY

Artificial intelligence in radiology
Gopal Vijayaraghavan, MD, MPH
University of Massachusetts Medical School
Worcester, MA

 

Refining Heredity Risk - Hall 4B
Moderator: Olufunmilayo (Funmi) Olopade, MD, FACP
University of Chicago
Chicago, IL

Reclassifying VUS: New techniques can solve the puzzle once and for all
Sean V. Tavtigian, PhD
Huntsman Cancer Institute at the University of Utah
Salt Lake City, UT

Clinical management of moderate penetrance genes
Allison W. Kurian, MBBS, MD, MSc
Stanford University School of Medicine
Palo Alto, CA

Polygenic risk score: Should clinicians use it
Montserrat García-Closas, MD, DrPH
National Cancer Institute
Rockville, MD

Panel Discussion

Evidence Based Integrative Therapies - During and Beyond Treatment - Hall 4A
Moderator: Dawn L. Hershman, MD, MS
Columbia University
Herbert Irving Comprehensive Cancer Center
New York, NY

Acupuncture
Ting Bao, MD, DABMA, MS
Memorial Sloan Kettering Cancer Center
New York, NY

Hypnosis and mindfulness
David Spiegel, MD
Stanford University
Stanford, CA

Complementary treatments
Donald Abrams, MD
University of California, San Francisco
San Francisco, CA

What does diet and exercise change really do for you
Nicole Simone, MD
Thomas Jefferson University
Philadelphia, PA

Panel Discussion

 
 
     
7:00 pm - 8:45 pm CT OPEN SATELLITE EVENT  In-person Symposia will be held at the San Antonio Marriott Rivercenter hotel.
 
  What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of ER-Positive Breast Cancer (Part 1 of a 3-Part CME Series) presented by Research To Practice  
  Register for this complimentary in-person symposia or virtual event: http://www.researchtopractice.com/Meetings/SA2021
 
     
7:30 pm - 9:00 pm CT  OPEN SATELLITE EVENT  In-person Symposia will be held at the San Antonio Marriott Rivercenter hotel.   
  Optimizing Immunotherapy in Triple Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Based Efficacy Monitoring presented by Your CE Source  
  Register for this complimentary in-person symposia or virtual event: https://www.cvent.com/d/c8qm17

Oncocyte is supporting this with a non commercial educational grant.
 

 
Tuesday | Wednesday | Thursday | Friday